376
Panorama Actual del Medicamento
REVISIÓN
Bibliografía
(cont.)
Web de interés
–
–
Diao D, Wright JM, Cundiff DK, Gueyffier F.
Pharma-
cotherapy for mild hypertension.
Cochrane Database Syst
Rev.
2012 Aug 15; 8: CD006742. doi: 10.1002/14651858.
CD006742.pub2.
–
–
Consejo General de Colegios Oficiales de Farmacéuti-
cos (CGCOF).
Plan estratégico para el desarrollo de la Aten-
ción Farmacéutica: hipertensión (resultados).
Panorama Ac-
tual Med
2008; 32(314): 605-15.
–
–
Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmie-
der RE, Böhm M. Symplicity HTN-2 Investigators.
Renal
sympathetic denervation in patients with treatment-resistant
hypertension (The Symplicity HTN-2 Trial): a randomised
controlled trial.
Lancet
2010; 376: 1903-9. doi: 10.1016/
S0140-6736(10)62039-9
–
–
Estruch R, Ros E, Salas-Salvadó J, Covas MI, D Pharm,
Corella D, Arós F, et al; the PREDIMED Study Investi-
gators.
Primary prevention of cardiovascular disease with a
mediterranean diet.
N Engl J Med
. 2013; 368(14): 1279-90.
doi: 10.1056/NEJMoa1200303.
–
–
Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille
MH, Duh MS.
Initial combination therapy reduces the risk
of cardiovascular events in hypertensive patients. A matched
cohort study.
Hypertension
2013; 61: 309-18. doi: 10.1161/
HYPERTENSIONAHA.112.201566.
–
–
Kalita J, Misra UK, Kumar B.
Is beta-blocker (atenolol) a
preferred antihypertensive in acute intracerebral hemorr-
hage?
Neurol Sci
. 2012 Oct 9. doi: 10.1007/s10072-012-
1210-y
–
–
Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S.
Concurrent
use of diuretics, angiotensin converting enzyme inhibitors,
and angiotensin receptor blockers with non-steroidal anti-
inflammatory drugs and risk of acute kidney injury: nested
case-control study.
BMJ
2013; 346: e8525. doi: 10.1136/
bmj.e8525
–
–
Llisterri JL, Rodriguez-Roca GC, Escobar C, Alonso-Mo-
reno FJ, Prieto MA, Barrios V, González-Alsina D, Divi-
són JA, Pallarés V, Beato P; Working Group of Arterial
Hypertension of the Spanish Society of Primary Care
Physicians Group HTASEMERGEN; PRESCAP 2010 in-
vestigators.
Treatment and blood pressure control in Spain
during 2002-2010.
J Hypertens
. 2012; 30(12): 2425-31. doi:
10.1097/HJH.0b013e3283592583.
–
–
Mann JF, Schmieder RE, McQueen M, Dyal L, Schuma-
cher H, Pogue J, et al.; ONTARGET investigators.
Renal
outcomes with telmisartan, ramipril, or both, in people at
high vascular risk (the ONTARGET study): a multicentre, ran-
domised, double-blind, controlled trial.
Lancet
2008; 372:
547-53.
–
–
O’Connor PJ, Trower NS, Vazquez-Benitez G, Desai JR,
Schmittdiel JA, Margolis KR, et al.
Benefits of early hyper-
tension control on cardiovascular outcomes inpatients with
diabetes.
Diabetes Care
2013; 36(2): 322-7. doi: 10.2337/
dc12-0284.
–
–
Olives C, Myerson R, Mokdad AH, Murray CJ, Lim SS.
Prevalence, awareness, treatment, and control of hyperten-
sion in United States counties, 2001-2009.
PLoS One
. 2013;
8(4): e60308. doi: 10.1371/journal.pone.0060308.
–
–
Organización Mundial de la Salud (OMS).
¿Es la hiper-
tensión un problema frecuente?
-
res/qa/82/es/index.html; mayo 2012.
–
–
Pande S, Hiller JE, Nkansah N, Bero L.
The effect of phar-
macist-provided non-dispensing services on patient outco-
mes, health service utilisation and costs in low- and middle-
income countries. Cochrane Database Syst Rev. 2013 Feb
28; 2: CD010398. doi: 10.1002/14651858.CD010398.
–
–
Rothwell PM, Howard SC, Dolan E, Dobson JE, Dahlöf
JE , Sever PS et al.
Prognostic factor significance of visit-to-
visit variability, maximum systolic blood pressure, and episo-
dic hypertension.
Lancet
2010; 375: 895-905.
–
–
Rothwell PM.
Limitations of the usual blood-pressure hypo-
thesis and importance of variability, instability, and episodic
hypertension.
Lancet
2010; 375: 938-48.
–
–
Selmer R, Blix HS, Landmark K, Reikvam A.
Choice of
initial antihypertensive drugs and persistence of drug use--a
4-year follow-up of 78,453 incident users.
Eur J Clin Phar-
macol
. 2012; 68(10): 1435-42. doi: 10.1007/s00228-012-
1261-2.
–
–
Shah N, Mason J, Kurt M, Denton B, Schaefer A, Mon-
tori V et al.
Comparative effectiveness of guidelines for the
management of hyperlipidemia and hypertension for type 2
diabetes patients.
PLoS ONE
. 2011; 6(1): e16170.
–
–
Sicras A, Velasco S, Navarro R.
Perfil de comorbilidad,
grado de control, uso de recursos sanitarios y presencia de
evento cardiovascular en sujetos con hipertensión arterial en
el ámbito de la atención primaria de salud.
Hipertens Riesg
Vasc.
2009; 26(5): 201-12.
–
–
Tamargo Menéndez J, Barana Muñoz A.
Terapéutica de
la hipertensión. En:
Terapéutica farmacológica de los tras-
tornos cardiovasculares, renales y hematológicos.
Madrid:
Consejo General de Colegios Oficiales de Farmacéuticos;
2012. pp. 249-266.
–
–
Wald NJ, Law MR.
A strategy to reduce cardiovascular di-
sease by more than 80%.
BMJ
. 2003; 326(7404): 1419.
–
–
Wille E, Scholze J, Alegría E, ferri C, Langham S, Ste-
vens W et al.
Modelling the costs of care of hypertension in
patients with metabolic syndrome and its consequences, in
Germany, Spain And Italy.
Eur J Health Econom
2010; 12(3):
205-18. doi: 10.1007/s10198-010-0223-9.
–
–
Wisloff T, Selmer R, Halvorsen S, Fretheim A, Norheim O,
Kristiansen I.
Choice of generic antihypertensive drugs fir the
primary prevention of cardiovascular disease – A cost-effecti-
veness analysis.
BMC Cardiovascular Disorders
. 2012; 12: 26.
–
–
Sociedad Española de Hipertensión - Liga Española para la lucha contra la hipertensión arterial.
/
–
–
World Hypertension League (Liga Mundial de la Hipertensión).
